Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

 
• By Sten Stovall
Sickle cells
Sevuparin is an anti-adhesive drug now in Phase II Trials in "core" SCD countries • Source: Shutterstock

More from Strategy

More from Business